[Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis]

Abstract

Dimethyl fumarate (DMF) is a new oral option for disease-modifying therapy (DMT) in patients with remitting multiple sclerosis as a first line treatment. The results of international randomized studies comparing DMF with placebo and other DMTs are presented. DMF is a DMT with promised efficacy and favorable safety profile that could be a treatment option for patients with suboptimal response for other first line DMTs and used as initial therapy for treatment-naive patients with unfavorable prognostic factors.

Keywords: dimethyl fumarate; disease-modifying therapy; fingolimod; glatiramer acetate; interferon β; multiple sclerosis; natalizimab; progressive multifocal leukoencephalopathy; teriflunomide.